Asociación entre puntaje de gleason, nivel de psa, dpsa y volumen prostático en una serie de pacientes con adenocarcinoma de próstata

Autores:: Benedetti Padrón, Inés
Barrios García, Lía
Segovia Fuentes, Javier

Tipo de recurso:: Article of journal

Fecha de publicación:: 2020

Institución:: Universidad de Cartagena

Repositorio:: Repositorio Universidad de Cartagena

Idioma:: spa

id	UCART2_75fb848b4ba369c1482315b4efbc1788
oai_identifier_str	oai:repositorio.unicartagena.edu.co:11227/13421
network_acronym_str	UCART2
network_name_str	Repositorio Universidad de Cartagena
repository_id_str
dc.title.spa.fl_str_mv	Asociación entre puntaje de gleason, nivel de psa, dpsa y volumen prostático en una serie de pacientes con adenocarcinoma de próstata
dc.title.translated.eng.fl_str_mv	Asociación entre puntaje de gleason, nivel de psa, dpsa y volumen prostático en una serie de pacientes con adenocarcinoma de próstata
title	Asociación entre puntaje de gleason, nivel de psa, dpsa y volumen prostático en una serie de pacientes con adenocarcinoma de próstata
spellingShingle	Asociación entre puntaje de gleason, nivel de psa, dpsa y volumen prostático en una serie de pacientes con adenocarcinoma de próstata Próstata Adenocarcinoma prostático Puntaje de Gleason Antígeno prostático específico (PSA) Densidad de antígeno prostático específico (DPSA).
title_short	Asociación entre puntaje de gleason, nivel de psa, dpsa y volumen prostático en una serie de pacientes con adenocarcinoma de próstata
title_full	Asociación entre puntaje de gleason, nivel de psa, dpsa y volumen prostático en una serie de pacientes con adenocarcinoma de próstata
title_fullStr	Asociación entre puntaje de gleason, nivel de psa, dpsa y volumen prostático en una serie de pacientes con adenocarcinoma de próstata
title_full_unstemmed	Asociación entre puntaje de gleason, nivel de psa, dpsa y volumen prostático en una serie de pacientes con adenocarcinoma de próstata
title_sort	Asociación entre puntaje de gleason, nivel de psa, dpsa y volumen prostático en una serie de pacientes con adenocarcinoma de próstata
dc.creator.fl_str_mv	Benedetti Padrón, Inés Barrios García, Lía Segovia Fuentes, Javier
dc.contributor.author.spa.fl_str_mv	Benedetti Padrón, Inés Barrios García, Lía Segovia Fuentes, Javier
dc.subject.spa.fl_str_mv	Próstata Adenocarcinoma prostático Puntaje de Gleason Antígeno prostático específico (PSA) Densidad de antígeno prostático específico (DPSA).
topic	Próstata Adenocarcinoma prostático Puntaje de Gleason Antígeno prostático específico (PSA) Densidad de antígeno prostático específico (DPSA).
publishDate	2020
dc.date.accessioned.none.fl_str_mv	2020-12-28 00:00:00
dc.date.available.none.fl_str_mv	2020-12-28 00:00:00
dc.date.issued.none.fl_str_mv	2020-12-28
dc.type.spa.fl_str_mv	Artículo de revista
dc.type.coar.fl_str_mv	http://purl.org/coar/resource_type/c_2df8fbb1
dc.type.version.spa.fl_str_mv	info:eu-repo/semantics/publishedVersion
dc.type.coarversion.spa.fl_str_mv	http://purl.org/coar/version/c_970fb48d4fbd8a85
dc.type.coar.spa.fl_str_mv	http://purl.org/coar/resource_type/c_6501
dc.type.content.spa.fl_str_mv	Text
dc.type.driver.spa.fl_str_mv	info:eu-repo/semantics/article
dc.type.local.eng.fl_str_mv	Journal article
format	http://purl.org/coar/resource_type/c_6501
status_str	publishedVersion
dc.identifier.issn.none.fl_str_mv	2215-7840
dc.identifier.uri.none.fl_str_mv	https://hdl.handle.net/11227/13421
dc.identifier.doi.none.fl_str_mv	10.32997/rcb-2012-3168
dc.identifier.eissn.none.fl_str_mv	2389-7252
dc.identifier.url.none.fl_str_mv	https://doi.org/10.32997/rcb-2012-3168
identifier_str_mv	2215-7840 10.32997/rcb-2012-3168 2389-7252
url	https://hdl.handle.net/11227/13421 https://doi.org/10.32997/rcb-2012-3168
dc.language.iso.spa.fl_str_mv	spa
language	spa
dc.relation.ispartofjournal.spa.fl_str_mv	Revista Ciencias Biomédicas
dc.relation.bitstream.none.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3168/2695
dc.relation.citationedition.spa.fl_str_mv	Núm. 1 , Año 2012
dc.relation.citationendpage.none.fl_str_mv	68
dc.relation.citationissue.spa.fl_str_mv	1
dc.relation.citationstartpage.none.fl_str_mv	58
dc.relation.citationvolume.spa.fl_str_mv	3
dc.relation.references.spa.fl_str_mv	Globocan 2008, cancer fact sheet, Prostate cancer Incidence and mortality worldwide in 2008. http://globocan.iarc.fr/factsheets/cancers/prostate.asp consultado, 9-diciembre 2010. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer J for Clinicians. 2011;61:69-90. Instituto Nacional de Cancerología, El cáncer en cifras, incidencia. http://www.cancer.gov.co/documentos/Incidencia/Tabla%2087.pdf consultado, 9-diciembre 2010. Instituto Nacional de Cancerología, El cáncer en cifras, mortalidad. http://www.cancer.gov.co/documentos/Mortalidad/Mortalidad%20nacional%20por%20tipo%20de%20c%C3%A1ncer%202000-2006%20.pdf consultado, 9-diciembre 2010. Routh JC, Leibovich BC. Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo ClinProc. 2005;80:899–907. Chodak G. Prostate cancer: epidemiology, screening and biomarkers. Rev Urology. 2006;8(suppl 2):S3-S8. Shah RB, Zhou M, LeBlanc S, Rubin MA. Comparison of the basal cell-specific markers, 34betaE12 and p63 in the diagnosis of prostate cancer. Am J Surg Pathol. 2002;26:1161-1168. Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol. 2007;60:34-42. Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Modern Pathology. 2004;17:292-306. Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;50:125-128. Bostwick DG. Grading prostate cancer. Am J Clin Pathol. 1994;102:S38-56. Eggener SE. Scardino PT. Walsh PC. Han M; Partin AW. et al, Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy. Journal of Urology. 2011;185:869-875. Chikezie O. Madu and Yi Lu. Novel diagnostic biomarkers for prostate cancer. J of Cancer. 2010;1:150-177. Jansen FH, Roobol M, Jenster G, Schroder FH, Bangma C. Screening for Prostate Cancer in 2008 II: The Importance of Molecular Subforms of Prostate-Specific Antigen and Tissue Kallikreins. European Urology. 2009;55(3):563-574. Stephan C, Cammann H, Meyer H, Lein M, Jung K. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Letters. 2007;249:18-29. Smith DS, Catalona WJ, Herschman JC. Longitudinal screening for prostate cancer with prostate speciﬁc antigen. JAMA. 1996;276:1309-1315. Babaian RJ, Fritsche HA, Evans RB. Prostate specific antigen and the prostate gland volume: correlation and clinical application. J Clin Lab Anal.1990;4:135-137. Scott G, Cavallo C, Lowe F. Evidence suggesting PSA cutpoint of 2.5 ng/ml for prompting prostate biopsy: review of 36,316 biopsies. Urology. 2005;65:549-553. D’Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135. Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-speciﬁc antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161. Lokner DH, Crawforded RE, Miller GJ. Prostate-specific antigen and prostate-specific antigen density in cases of pathologically proven prostate cancer. J Urol. 1993;149:414-420. Brawer MK, Aramburu D, Chen GL. The inability of prostate-specificantigen index to enhance the predictive value of prostate-specific antigen in the diagnosis of prostatic carcinoma. J urol. 1993; 150(2p):369-373. Rodríguez A, González A. Importancia de la velocidad y la densidad de PSA en la predicción de cáncer de próstata en la pieza de RTU o adenomectomía de pacientes con biopsia prostática previa negativa. Actas Urol Esp. 2008;32:779-786. Al-Azab R, Toi A, Lockwood G, Kulkarni G, Fleshner N. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-Guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology. 2007;69:103-107. Klein LT, Lowe FC. The effects of prostatic manipulation on prostate-specific antigen levels. Urol Clin North Am. 1997;24:293-297. Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004;172:1297-1301. Reis L O, Zani E L, Alonso J.C, Simões F A, Rejowski R F, Ferreira U. ¿Impacta el criterio para indicar la biopsia prostática sobre su exactitud? Estudio prospectivo llevado a cabo sobre una población de pacientes ambulantes. Actas Urológicas Españolas. 2011;35:10-14. Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283–1290. Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Acta Urol Esp. 2009;33:113-126. Piovesan AC, de Campos Freire G, Miranda FC, Cordeiro P, Yamada R, Srougi M. Incidence of Histological Prostatitis And Its Correlation With PSA Density. Clinics. 2009;64:1049-1051. Seaman EK, Whang IS, Cooner W, Olsson CA, Benson MC. Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate. Urology. 1994;43:645-648. Benson MC, Whang IH, Olsson CA, McMahon DJ, and Cooner WH. The use of prostatic specific antigen density to enhance the predictive value of intermediate levels of serum prostatic specific antigen. J Urol. 1992;147:817-821. Lodeta B, Benko G, Car S, Filipan Z, Stajcar D, Dujmović T. Prostate specific antigen density can help avoid unnecessary prostate biopsies at prostate specific antigen range of 4-10 ng/ml Acta Clin Croat. 2009; 48:153-155. Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152: 2031-2036. Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000;56:255-260. Stamey TA, Johnstone IM, McNeal JE, et al. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml. Correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol. 2002;167:103-111. Bazinet M, Meshref AW, Trudel C, Aronson S, Peloquin F, Nachabe M, Begin LR, and Elhilali MM. Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology. 1994;43:44-52. Uzzo R G,Wei J T,Waldbaum et al. The influence of prostate size in cáncer detection, Urology. 1995;46:831-836. Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum PSA values. J Urol. 1994;151:1571- 1574. Kundu S.D, Roehl K.A, Yu X, Antenor JA, Suarez BK, Catalona WJ. Prostate Specific Antigen Density Correlates with Features of Prostate Cancer Aggressiveness. J Urology. 2007;177:505- 509. Moussa AS, Li J, Soriano M, et al. Prostate biopsy clinical and pathologic variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int. 2009;103:43-48. Tilki D, Schlenker B, John M, et al. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: Results from a single institution series. Urologic Oncology: Seminars and Original Investigations, 2009;29(5):508-514. Gyasi-Sarpong K, Boateng K, Aboah K, Opoku P, Adu Gyamfi M. Correlation of Pre-operative Prostate Specific Antigen (PSA) With Gleason Grading in Prostate Cancer Diagnosis. Urology 2008:72 (suppl):S122-S123. Al Shakarchi J A, Wasfi D. Audit of PSA and Gleason scoring in prostatic carcinoma. European Urology Supplements. 2009;8:567. Giannarini G, Scott C A, Moro U, Pertoldi B, Beltrami C A, Selli C. Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer? Urologic Oncolo. 2008;24(4):353-360. Ohori J, Dunn K P, Scardino P. Is Prostate-Specific Antigen Density More Useful Than Prostate-Specific Antigen Levels In The Diagnosis Of Prostate Cancer? Urology. 1995;46:666-671.
dc.rights.spa.fl_str_mv	Revista Ciencias Biomédicas - 2020
dc.rights.uri.spa.fl_str_mv	https://creativecommons.org/licenses/by-nc-sa/4.0/
dc.rights.coar.spa.fl_str_mv	http://purl.org/coar/access_right/c_abf2
dc.rights.accessrights.spa.fl_str_mv	info:eu-repo/semantics/openAccess
rights_invalid_str_mv	Revista Ciencias Biomédicas - 2020 https://creativecommons.org/licenses/by-nc-sa/4.0/ http://purl.org/coar/access_right/c_abf2
eu_rights_str_mv	openAccess
dc.format.mimetype.spa.fl_str_mv	application/pdf
dc.publisher.spa.fl_str_mv	Universidad de Cartagena
dc.source.spa.fl_str_mv	https://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3168
institution	Universidad de Cartagena
bitstream.url.fl_str_mv	https://repositorio.unicartagena.edu.co/bitstreams/7c952ef1-307f-4c38-aaac-fc067853f8b6/download
bitstream.checksum.fl_str_mv	3cc951580381998c46117fda4ac9f227
bitstream.checksumAlgorithm.fl_str_mv	MD5
repository.name.fl_str_mv	Biblioteca Digital Universidad de Cartagena
repository.mail.fl_str_mv	bdigital@metabiblioteca.com
_version_	1818153138558861312
spelling	Benedetti Padrón, InésBarrios García, LíaSegovia Fuentes, Javier2020-12-28 00:00:002020-12-28 00:00:002020-12-282215-7840https://hdl.handle.net/11227/1342110.32997/rcb-2012-31682389-7252https://doi.org/10.32997/rcb-2012-3168application/pdfspaUniversidad de CartagenaRevista Ciencias Biomédicashttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/download/3168/2695Núm. 1 , Año 2012681583Globocan 2008, cancer fact sheet, Prostate cancer Incidence and mortality worldwide in 2008. http://globocan.iarc.fr/factsheets/cancers/prostate.asp consultado, 9-diciembre 2010.Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA: A Cancer J for Clinicians. 2011;61:69-90.Instituto Nacional de Cancerología, El cáncer en cifras, incidencia. http://www.cancer.gov.co/documentos/Incidencia/Tabla%2087.pdf consultado, 9-diciembre 2010.Instituto Nacional de Cancerología, El cáncer en cifras, mortalidad. http://www.cancer.gov.co/documentos/Mortalidad/Mortalidad%20nacional%20por%20tipo%20de%20c%C3%A1ncer%202000-2006%20.pdf consultado, 9-diciembre 2010.Routh JC, Leibovich BC. Adenocarcinoma of the prostate: epidemiological trends, screening, diagnosis, and surgical management of localized disease. Mayo ClinProc. 2005;80:899–907.Chodak G. Prostate cancer: epidemiology, screening and biomarkers. Rev Urology. 2006;8(suppl 2):S3-S8.Shah RB, Zhou M, LeBlanc S, Rubin MA. Comparison of the basal cell-specific markers, 34betaE12 and p63 in the diagnosis of prostate cancer. Am J Surg Pathol. 2002;26:1161-1168.Humphrey PA. Diagnosis of adenocarcinoma in prostate needle biopsy tissue. J Clin Pathol. 2007;60:34-42.Humphrey PA. Gleason grading and prognostic factors in carcinoma of the prostate. Modern Pathology. 2004;17:292-306.Gleason DF. Classification of prostatic carcinomas. Cancer Chemother Rep. 1966;50:125-128.Bostwick DG. Grading prostate cancer. Am J Clin Pathol. 1994;102:S38-56.Eggener SE. Scardino PT. Walsh PC. Han M; Partin AW. et al, Predicting 15-Year Prostate Cancer Specific Mortality After Radical Prostatectomy. Journal of Urology. 2011;185:869-875.Chikezie O. Madu and Yi Lu. Novel diagnostic biomarkers for prostate cancer. J of Cancer. 2010;1:150-177.Jansen FH, Roobol M, Jenster G, Schroder FH, Bangma C. Screening for Prostate Cancer in 2008 II: The Importance of Molecular Subforms of Prostate-Specific Antigen and Tissue Kallikreins. European Urology. 2009;55(3):563-574.Stephan C, Cammann H, Meyer H, Lein M, Jung K. PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. Cancer Letters. 2007;249:18-29.Smith DS, Catalona WJ, Herschman JC. Longitudinal screening for prostate cancer with prostate speciﬁc antigen. JAMA. 1996;276:1309-1315.Babaian RJ, Fritsche HA, Evans RB. Prostate specific antigen and the prostate gland volume: correlation and clinical application. J Clin Lab Anal.1990;4:135-137.Scott G, Cavallo C, Lowe F. Evidence suggesting PSA cutpoint of 2.5 ng/ml for prompting prostate biopsy: review of 36,316 biopsies. Urology. 2005;65:549-553.D’Amico AV, Chen MH, Roehl KA, et al. Preoperative PSA velocity and the risk of death from prostate cancer after radical prostatectomy. N Engl J Med. 2004;351:125-135.Catalona WJ, Smith DS, Ratliff TL, et al. Measurement of prostate-speciﬁc antigen in serum as a screening test for prostate cancer. N Engl J Med. 1991;324:1156-1161.Lokner DH, Crawforded RE, Miller GJ. Prostate-specific antigen and prostate-specific antigen density in cases of pathologically proven prostate cancer. J Urol. 1993;149:414-420.Brawer MK, Aramburu D, Chen GL. The inability of prostate-specificantigen index to enhance the predictive value of prostate-specific antigen in the diagnosis of prostatic carcinoma. J urol. 1993; 150(2p):369-373.Rodríguez A, González A. Importancia de la velocidad y la densidad de PSA en la predicción de cáncer de próstata en la pieza de RTU o adenomectomía de pacientes con biopsia prostática previa negativa. Actas Urol Esp. 2008;32:779-786.Al-Azab R, Toi A, Lockwood G, Kulkarni G, Fleshner N. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-Guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL. Urology. 2007;69:103-107.Klein LT, Lowe FC. The effects of prostatic manipulation on prostate-specific antigen levels. Urol Clin North Am. 1997;24:293-297.Stamey TA, Caldwell M, McNeal JE, Nolley R, Hemenez M, Downs J. The prostate specific antigen era in the United States is over for prostate cancer: what happened in the last 20 years? J Urol. 2004;172:1297-1301.Reis L O, Zani E L, Alonso J.C, Simões F A, Rejowski R F, Ferreira U. ¿Impacta el criterio para indicar la biopsia prostática sobre su exactitud? Estudio prospectivo llevado a cabo sobre una población de pacientes ambulantes. Actas Urológicas Españolas. 2011;35:10-14.Catalona WJ, Richie JP, Ahmann FR, et al. Comparison of digital rectal examination and serum prostate specific antigen in the early detection of prostate cancer: results of a multicenter clinical trial of 6,630 men. J Urol. 1994;151:1283–1290.Heidenreich A, Aus G, Bolla M, Joniau S, Matveev VB, Schmid HP, et al. EAU guidelines on prostate cancer. Acta Urol Esp. 2009;33:113-126.Piovesan AC, de Campos Freire G, Miranda FC, Cordeiro P, Yamada R, Srougi M. Incidence of Histological Prostatitis And Its Correlation With PSA Density. Clinics. 2009;64:1049-1051.Seaman EK, Whang IS, Cooner W, Olsson CA, Benson MC. Predictive value of prostate-specific antigen density for the presence of micrometastatic carcinoma of the prostate. Urology. 1994;43:645-648.Benson MC, Whang IH, Olsson CA, McMahon DJ, and Cooner WH. The use of prostatic specific antigen density to enhance the predictive value of intermediate levels of serum prostatic specific antigen. J Urol. 1992;147:817-821.Lodeta B, Benko G, Car S, Filipan Z, Stajcar D, Dujmović T. Prostate specific antigen density can help avoid unnecessary prostate biopsies at prostate specific antigen range of 4-10 ng/ml Acta Clin Croat. 2009; 48:153-155.Catalona WJ, Richie JP, deKernion JB, Ahmann FR, Ratliff TL, Dalkin BL, et al. Comparison of prostate specific antigen concentration versus prostate specific antigen density in the early detection of prostate cancer: receiver operating characteristic curves. J Urol. 1994;152: 2031-2036.Catalona WJ, Southwick PC, Slawin KM, Partin AW, Brawer MK, Flanigan RC, et al. Comparison of percent free PSA, PSA density, and age-specific PSA cutoffs for prostate cancer detection and staging. Urology. 2000;56:255-260.Stamey TA, Johnstone IM, McNeal JE, et al. Preoperative serum prostate specific antigen levels between 2 and 22 ng/ml. Correlate poorly with post-radical prostatectomy cancer morphology: prostate specific antigen cure rates appear constant between 2 and 9 ng/ml. J Urol. 2002;167:103-111.Bazinet M, Meshref AW, Trudel C, Aronson S, Peloquin F, Nachabe M, Begin LR, and Elhilali MM. Prospective evaluation of prostate-specific antigen density and systematic biopsies for early detection of prostatic carcinoma. Urology. 1994;43:44-52.Uzzo R G,Wei J T,Waldbaum et al. The influence of prostate size in cáncer detection, Urology. 1995;46:831-836.Keetch DW, Catalona WJ, Smith DS. Serial prostatic biopsies in men with persistently elevated serum PSA values. J Urol. 1994;151:1571- 1574.Kundu S.D, Roehl K.A, Yu X, Antenor JA, Suarez BK, Catalona WJ. Prostate Specific Antigen Density Correlates with Features of Prostate Cancer Aggressiveness. J Urology. 2007;177:505- 509.Moussa AS, Li J, Soriano M, et al. Prostate biopsy clinical and pathologic variables that predict significant grading changes in patients with intermediate and high grade prostate cancer. BJU Int. 2009;103:43-48.Tilki D, Schlenker B, John M, et al. Clinical and pathologic predictors of Gleason sum upgrading in patients after radical prostatectomy: Results from a single institution series. Urologic Oncology: Seminars and Original Investigations, 2009;29(5):508-514.Gyasi-Sarpong K, Boateng K, Aboah K, Opoku P, Adu Gyamfi M. Correlation of Pre-operative Prostate Specific Antigen (PSA) With Gleason Grading in Prostate Cancer Diagnosis. Urology 2008:72 (suppl):S122-S123.Al Shakarchi J A, Wasfi D. Audit of PSA and Gleason scoring in prostatic carcinoma. European Urology Supplements. 2009;8:567.Giannarini G, Scott C A, Moro U, Pertoldi B, Beltrami C A, Selli C. Are PSA density and PSA density of the transition zone more accurate than PSA in predicting the pathological stage of clinically localized prostate cancer? Urologic Oncolo. 2008;24(4):353-360.Ohori J, Dunn K P, Scardino P. Is Prostate-Specific Antigen Density More Useful Than Prostate-Specific Antigen Levels In The Diagnosis Of Prostate Cancer? Urology. 1995;46:666-671.Revista Ciencias Biomédicas - 2020https://creativecommons.org/licenses/by-nc-sa/4.0/http://purl.org/coar/access_right/c_abf2info:eu-repo/semantics/openAccesshttps://revistas.unicartagena.edu.co/index.php/cbiomedicas/article/view/3168PróstataAdenocarcinoma prostáticoPuntaje de GleasonAntígeno prostático específico (PSA)Densidad de antígeno prostático específico (DPSA).Asociación entre puntaje de gleason, nivel de psa, dpsa y volumen prostático en una serie de pacientes con adenocarcinoma de próstataAsociación entre puntaje de gleason, nivel de psa, dpsa y volumen prostático en una serie de pacientes con adenocarcinoma de próstataArtículo de revistainfo:eu-repo/semantics/publishedVersionhttp://purl.org/coar/version/c_970fb48d4fbd8a85http://purl.org/coar/resource_type/c_6501http://purl.org/coar/resource_type/c_2df8fbb1Textinfo:eu-repo/semantics/articleJournal articlePublicationOREORE.xmltext/xml2646https://repositorio.unicartagena.edu.co/bitstreams/7c952ef1-307f-4c38-aaac-fc067853f8b6/download3cc951580381998c46117fda4ac9f227MD5111227/13421oai:repositorio.unicartagena.edu.co:11227/134212024-09-05 15:30:36.818https://creativecommons.org/licenses/by-nc-sa/4.0/Revista Ciencias Biomédicas - 2020metadata.onlyhttps://repositorio.unicartagena.edu.coBiblioteca Digital Universidad de Cartagenabdigital@metabiblioteca.com

Asociación entre puntaje de gleason, nivel de psa, dpsa y volumen prostático en una serie de pacientes con adenocarcinoma de próstata

Publicaciones similares